Breaking News

Enveric Biosciences Creates Australia-based Subsidiary to Accelerate Lead Program

Clinical trial investigating Enveric’s lead product candidate, EB-373 targeting anxiety disorder expected to initiate in the fourth quarter of 2023.

Enveric Biosciences, a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, established Enveric Therapeutics Pty. Ltd., an Australia-based subsidiary, to support the company’s plans to advance its EVM201 Series, including lead candidate EB-373, towards the clinic. Enveric Therapeutics will oversee the company’s preclinical, clinical, and regulatory activities in Australia, including ongoing i...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters